ASCO
Pharmaceutical
The 2026 American Society of Clinical Oncology (ASCO) annual meeting delivered several potentially practice-changing datasets across solid tumors and hematologic malignancies, while underlining the growing influence of Chinese biotech innovation, antibody-drug conjugates and next-generation targeted therapies. 4 June 2026
Today's issue
Refine search
Biotechnology
Deciding which company has presented the most significant data at an ASCO meeting is often a matter of perspective, but Amgen is definitely a contender at this year's event. 3 June 2019
Pharmaceutical
Japan’s Takeda Pharmaceutical has presented new data for TAK-788 during an oral session at the 2019 American Society of Clinical Oncology (ASCO) annual meeting. 3 June 2019
Pharmaceutical
An interim analysis of the Phase III ENZAMET trial has found that 80% of men with metastatic hormone-sensitive prostate cancer who received Xtandi (enzalutamide) along with standard-of-care treatment were alive at three years. 3 June 2019
Biotechnology
Merck & Co’s industry-leading immuno-oncology drug Keytruda (pembrolizumab) is no stranger to making the headlines at ASCO, and this year’s meeting is no exception. 3 June 2019
Pharmaceutical
Swiss pharma giant Novartis has released data showing statistically-significant overall survival (OS) results for the CDK4/6 inhibitor Kisqali (ribociclib), in combination with endocrine therapy. 3 June 2019
Biotechnology
Much awaited Phase III POLO trial data were presented at the 2019 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, and showed that Lynparza (olaparib) has a significant impact of progression of disease in certain pancreatic cancer patients. 3 June 2019
Biotechnology
Positive data at the annual meeting of the American Society of Clinical Oncology (ASCO) will help boost chances for Sanofi’s isatuximab in a looming head-to-head with Johnson & Johnson’s Darzalex (daratumumab). 3 June 2019
Biotechnology
Immunotherapy specialist Atara Biotherapeutics has presented clinical results relating to its biomarker research at the annual meeting of the American Society of Clinical Oncology (ASCO). 3 June 2019
Biotechnology
New baseline biomarker analyses and updated clinical study efficacy and safety results were shared in a presentation, titled "Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214, bempeg), at the 2019 American Society of Clinical Oncology (ASCO) meeting in Chicago. 3 June 2019
Pharmaceutical
Janssen Pharmaceutical companies presented positive findings from the investigational Phase III TITAN study, which showed the addition of Erleada (apalutamide) to androgen deprivation therapy (ADT) compared with placebo plus ADT significantly improved the dual primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). 1 June 2019
Pharmaceutical
Results of a new post-hoc analysis showed that treatment with darolutamide plus androgen deprivation therapy (ADT) delays worsening of disease-related symptoms and maintains quality of life beyond end of study treatment compared to placebo plus ADT in men with non-metastatic castration-resistant prostate cancer. 1 June 2019
Pharmaceutical
French drugmaker Ipsen is to present new data on three of its drugs at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting – namely Cabometyx (cabozantinib), Onivyde (irinotecan) and Somatuline/Somatuline Depot (lanreotide autogel). 24 May 2019
Biotechnology
As industry majors prepare to make a splash at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), 2003-founded nanomedicine specialist Nanobiotix hopes it can punch above its weight. 24 May 2019
Biotechnology
It’s ASCO time again. The annual meeting of the American Society of Clinical Oncology (ASCO) is now almost upon us, with the event due to start in Chicago on Friday, May 31. 22 May 2019
Biotechnology
When it comes to long-term investment in pharma stocks, looking at pipeline assets at a pre-clinical or early clinical stage gives as good a clue as any as to where the value lies. 17 May 2019
Pharmaceutical
Basel, Switzerland-based pharma giant Novartis has provided an outline of the data it intends to present at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. 17 May 2019
Biotechnology
New Jersey, USA-based Merck & Co has announced it will present 140 abstracts at the upcoming annual meeting of the Annual Society of Clinical Oncology (ASCO), including on the anti-PD-1 blockbuster Keytruda (pembrolizumab) and Lynparza (olaparib) - in over 25 types of cancer. 17 May 2019
Pharmaceutical
The world’s biggest pharma company has talked up its data ahead of the world’s biggest pharma conference. 16 May 2019
Biotechnology
After a slow start, there have been better recent sales of Yescarta (axicabtagene ciloleucel), the CAR-T therapy that Gilead Sciences picked up in its $11.9 billion acquisition of Kite Pharma in 2017. 16 May 2019
Pharmaceutical
London-listed AstraZeneca has revealed details of what it will present at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) at the end of May. 16 May 2019
Pharmaceutical
The 2026 American Society of Clinical Oncology (ASCO) annual meeting delivered several potentially practice-changing datasets across solid tumors and hematologic malignancies, while underlining the growing influence of Chinese biotech innovation, antibody-drug conjugates and next-generation targeted therapies. 4 June 2026
Biotechnology
US biotech company Celcuity reported detailed Phase III data for its investigational PI3K/AKT/mTOR inhibitor gedatolisib at the American Society of Clinical Oncology (ASCO) Annual Meeting, showing a significant progression-free survival (PFS) benefit in hormone receptor-positive, HER2-negative, PIK3CA-mutant advanced breast cancer. 3 June 2026
Biotechnology
US biotech Kelonia Therapeutics has reported updated early-stage data for KLN-1010, its in vivo CAR-T candidate for relapsed or refractory multiple myeloma, offering a fuller look at the program behind Eli Lilly’s planned acquisition. 2 June 2026
Pharmaceutical
US pharma major Eli Lilly’s Verzenio (abemaciclib) significantly delayed disease progression in patients with advanced dedifferentiated liposarcoma, according to Phase III SARC041 data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. 1 June 2026
Biotechnology
Chinese biotech company Akeso has reported an overall survival (OS) benefit for ivonescimab plus chemotherapy in a Phase III lung cancer study, adding to growing interest in the PD-1/VEGF bispecific antibody as a potential competitor in first-line non-small cell lung cancer (NSCLC). 1 June 2026
Pharmaceutical
US oncology company Revolution Medicines has reported Phase III data showing that its investigational RAS inhibitor daraxonrasib significantly extended survival in previously-treated metastatic pancreatic ductal adenocarcinoma (PDAC), one of the most difficult cancers to treat. 1 June 2026
Pharmaceutical
US pharma giant Pfizer has reported a Phase III win for Talzenna (talazoparib) plus Xtandi (enzalutamide), setting up a potential broader role for the regimen in metastatic castration-sensitive prostate cancer. 1 June 2026
Biotechnology
German biotech BioNTech and and US pharma major Bristol Myers Squibb announced interim Phase II data from the global Phase II/III ROSETTA Lung-02 clinical trial evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig (also known as BNT327 or BMS-986545) plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC). 1 June 2026
Pharmaceutical
US pharma major Bristol Myers Squibb shared data at the American Society of Clinical Oncology (ASCO) annual meeting Friday that demonstrated its CELMoD candidate mezigdomide more than doubled progression-free survival in patients with relapsed or refractory multiple myeloma. 29 May 2026
Biotechnology
Taiwanese biotech PharmaEssentia is preparing to seek an expanded US label for its long-acting interferon Besremi (ropeginterferon alfa-2b) following new late-stage data that show the therapy outperforms anagrelide in treating essential thrombocythaemia (ET) after hydroxyurea failure. 3 June 2025
Pharmaceutical
Detailed results from the Phase III OASIS-4 study have found that Bayer’s elinzanetant showed a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flushes) from baseline to week four and 12 compared to placebo, in women taking endocrine therapy to prevent hormone receptor (HR+) breast cancer. 2 June 2025
Pharmaceutical
Positive results from the SERENA-6 Phase III trial have shown that AstraZeneca’s camizestrant alongside a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) led to a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS). 2 June 2025
Biotechnology
The Alliance for Clinical Trials in Oncology has announced results from ATOMIC, a Phase III trial evaluating standard chemotherapy alone or combined with Roche’s Tecentriq (atezolizumab) in patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). 2 June 2025
Biotechnology
With ASCO 2025 drawing toward its close in Chicago, Amsterdam-based biotech Avidicure is entering the spotlight with its first public data on a new class of cancer immunotherapies. The company’s lead program, AVC-S-101, is designed to target TROP2 in non-small cell lung cancer (NSCLC) and other solid tumors. 2 June 2025
Biotechnology
US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 inhibitor Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. 2 June 2025
Biotechnology
AstraZeneca has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its immunotherapy Imfinzi (durvalumab) to significantly delay disease progression in patients with early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers. 2 June 2025
Pharmaceutical
Arcus Biosciences is setting the stage for a high-stakes Phase III showdown in kidney cancer, after early results showed that nearly half of patients treated with its experimental therapy had a confirmed response. 2 June 2025
Pharmaceutical
US drugmaker Protagonist Therapeutics and Japan’s Takeda Pharma announced detailed results from the Phase III, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. 2 June 2025
Pharmaceutical
Arvinas and Pfizer today announced detailed results from the Phase III VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. 2 June 2025
Pharmaceutical
US pharma giant Pfizer on Saturday announced statistically-significant and clinically-meaningful survival results from the Phase III BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. 2 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze